Checkmate's CMP-001 among TLR9 agonist combo data highlighted at AACR

Data from combination treatment with toll-like receptor 9 agonists and PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) were presented at the American Association for Cancer Research meeting in Chicago on Tuesday.

Checkmate Pharmaceuticals Inc. (Cambridge, Mass.) reported data from the CMP-001 plus Keytruda arm of the Phase Ib CMP-001-001 trial in patients with advanced melanoma resistant to prior anti-PD-1 treatment. Checkmate CEO Art Krieg told BioCentury the response rate to PD-1/PD-L1 monotherapy in this population is about 6%...